Ardent Health, Inc. ARDT
- Market cap
- $1.5B
- P/E
- 19.2×
Follow ARDT
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | 14.58 | 8.28 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | — | — | — | 20.72 | 17.29 |
High Price
|
|||
| — | — | — | — | — | — | — | 24,200 | 24,900 | 25,200 |
Employees
|
|||
| — | — | — | — | — | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | 4,870 | 5,130 | 5,409 | 5,966 | 6,324 |
Revenue
|
|||
| — | — | — | — | — | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Gross Margin
|
|||
| — | — | — | — | — | 296 | 311 | 152 | 363 | 286 |
EBT
|
|||
| — | — | — | — | — | 6.08% | 6.07% | 2.80% | 6.09% | 4.53% |
EBT Margin
|
|||
| — | — | — | — | — | 245 | 265 | 129 | 300 | 230 |
Net Income
|
|||
| — | — | — | — | — | 144 | 144 | 146 | 152 | 160 |
Depreciation
|
|||
| — | — | — | — | — | 0.00 | 40.67 | 42.89 | 45.05 | 44.93 |
Revenue/Sh
|
|||
| — | — | — | — | — | — | 2.10 | 1.02 | 1.59 | 0.96 |
Earnings/Sh
|
|||
| — | — | — | — | — | 0.00 | (0.30) | 1.76 | 2.38 | 3.34 |
Cash Flow/Sh
|
|||
| — | — | — | — | — | 0.00 | (1.20) | (1.09) | (1.42) | (1.51) |
Capex/Sh
|
|||
| — | — | — | — | — | 0.00 | (1.50) | 0.67 | 0.96 | 1.84 |
Free CF/Sh
|
|||
| — | — | — | — | — | 0.00 | 8.24 | 8.52 | 11.49 | 11.98 |
Book Value/Sh
|
|||
| — | — | — | — | — | — | 126 | 126 | 132 | 141 |
Shares
|
|||
| — | — | — | — | — | 11.06 | 11.06 | 11.06 | 9.97 | 9.10 |
PE Ratio
|
|||
| — | — | — | — | — | 0.36 | 0.36 | 0.36 | 0.38 | 0.20 |
PS Ratio
|
|||
| — | — | — | — | — | 1.75 | 1.75 | 1.75 | 1.49 | 0.74 |
PB Ratio
|
|||
| — | — | — | — | — | 0.49 | 0.49 | 0.49 | 0.47 | 0.26 |
EV/Sales
|
|||
| — | — | — | — | — | 23.86 | 23.86 | 23.86 | 21.96 | 6.31 |
EV/FCF
|
|||
| — | — | — | — | — | 147 | (38) | 222 | 315 | 471 |
Op' Cash Flow
|
|||
| — | — | — | — | — | (135) | (151) | (137) | (188) | (212) |
Capex
|
|||
| — | — | — | — | — | 11 | (189) | 84 | 128 | 259 |
FCF
|
|||
| — | — | — | — | — | — | 601 | 624 | 887 | 1,012 |
Working Cap'
|
|||
| — | — | — | — | — | — | 1,178 | 1,187 | 1,095 | 1,099 |
Total Debt
|
|||
| — | — | — | — | — | — | 722 | 749 | 538 | 390 |
Net Debt
|
|||
| — | — | — | — | — | 0 | 1,040 | 1,075 | 1,521 | 1,686 |
Sh' Equity
|
|||
| — | — | — | — | — | 0.00% | 8.44% | 1.17% | 4.34% | 2.65% |
ROA
|
|||
| — | — | — | — | — | 0.00% | 7.70% | 7.68% | 12.31% | 9.80% |
ROIC
|
|||
| — | — | — | — | — | 0.00% | 0.00% | 5.10% | 16.20% | 8.47% |
ROE
|
|||
Ardent Health, Inc. peers in Medical Care Facilities
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| HCSG Healthcare Services Group, Inc. | $1.4B | 12.2× | Compare |
| NUTX Nutex Health Inc. | $1.4B | 8.4× | Compare |
| PNTG The Pennant Group, Inc. | $1.4B | 43.4× | Compare |
| AMN AMN Healthcare Services Inc | $1.3B | 12.8× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ASTH Astrana Health, Inc. | $1.7B | 43.6× | Compare |
| AGL Agilon Health, Inc. | $1.3B | 0.0× | Compare |
| USPH U.S. Physical Therapy, Inc. | $1.3B | 499× | Compare |
| SNDA Sonida Senior Living, Inc. | $1.8B | 0.0× | Compare |
Ardent Health, Inc. (ARDT) key facts
- Ardent Health, Inc. (ARDT) is a Medical Care Facilities company in the Healthcare sector, listed on the New York Stock Exchange.
- Ardent Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.3 billion, up 6.01% from fiscal 2024.
- As of September 25, 2026, ARDT traded at $10.54, a market capitalization of $1.5 billion.
- Return on equity was 8.47% and debt-to-equity 0.63.
Ardent Health, Inc. (ARDT) Latest News
11 Aug
Ardent Health (ARDT) released its Q2 2026 earnings call transcript covering quarterly financial results and operations. Quarterly earnings updates supply financial metrics that moderately shape near-term market views without guaranteeing major strategic shifts.
Oklahoma Heart Institute introduces new national cardiovascular trials and technologies to patients across the region. New trials at Oklahoma Heart Institute strengthen regional cardiovascular capabilities and innovation positioning.
8 Aug
Ardent Health reported weaker Q2 earnings and lowered guidance, leading to questions on whether the stock is undervalued at current levels. Lowered guidance and Q2 earnings miss can pressure near-term valuation and investor sentiment without fundamentally altering long-term operations.
5 Aug
Ardent Health Inc raised Impact Program savings targets in its Q2 2026 earnings call. Raising Impact Program savings targets signals enhanced cost management and potential margin improvements ahead.
Ardent Health Q2 earnings call highlighted financial results, operational updates and company outlook. Q2 earnings details can moderately influence stock performance and market perception of company health.
Ardent Health Partners, LLC held its Q2 2026 earnings call to report financial results and business updates. Routine quarterly earnings updates typically produce moderate effects on near-term stock sentiment without major strategic shifts.
4 Aug
Ardent Health, Inc. Q2 earnings missed analyst estimates. Q2 earnings miss pressures near-term stock price and sentiment.
Ardent Health, Inc. reported financial results for the second quarter of 2026. Quarterly earnings release reveals financial performance that may influence near-term stock sentiment but rarely shifts long-term trajectory alone.
23 Jul
Ardent Health surpasses 1 million patient encounters supported by ambient AI. Ambient AI scale to 1 million encounters signals operational efficiency gains in core patient services.
7 Jun
Ardent Health appoints new CEO after IPO, potentially redirecting strategy away from efficiency focus. New CEO appointment may moderately influence Ardent Health strategy and investor views post-IPO.
Ardent Health, Inc. (ARDT) appoints Dave Caspers as new CEO, triggering a valuation review of the company amid the leadership transition. New CEO appointment at Ardent Health introduces moderate strategic and market sentiment shifts without guaranteed fundamental trajectory changes.
3 Jun
Ardent Health appoints new CEO tasked with advancing existing growth plans. New CEO appointment may moderately shift strategy and investor views on expansion.
2 Jun
Ardent Health, Inc. appoints Dave Caspers as CEO. CEO appointment may moderately influence strategy and operations.
14 May
Ardent Health partners with Fujifilm to deploy Synapse Enterprise Imaging across all facilities for radiology and cardiology, enhancing diagnostic capabilities and workflow efficiency. Enterprise-wide rollout of advanced imaging technology strengthens operational efficiency and competitive positioning in core healthcare services.
8 May
Ardent Health, Inc. (ARDT) beat analyst earnings forecasts, prompting analysts to update their models. Earnings beat and analyst model updates signal strong financial performance, likely boosting ARDT's stock price and future outlook.
7 May
Ardent Health, Inc. (ARDT) released Q1 earnings call highlights detailing financial performance, operational updates, and future outlook. Q1 earnings call highlights disclose critical financial results and guidance that significantly shape ARDT's trajectory and investor sentiment.
6 May
Ardent Health (ARDT) released Q1 2026 earnings call transcript detailing quarterly financial performance, management discussion, and forward guidance. Q1 2026 earnings transcript discloses financial results and strategic outlook directly influencing ARDT's trajectory and investor sentiment.
Ardent Health Partners, LLC released its Q1 2026 earnings call summary, highlighting financial performance, operational updates, and future outlook for the quarter. Q1 2026 earnings call summary provides key financial results and guidance that significantly influence ARDT's market performance and investor sentiment.
5 May
Ardent Health, Inc. (ARDT) beat Q1 earnings and revenue estimates. Beating Q1 earnings and revenue estimates boosts investor sentiment and signals strong financial performance with significant short-to-medium term market impact.
Ardent Health, Inc. (ARDT) reported first quarter 2026 results. Quarterly earnings releases like Q1 2026 results directly impact financial performance metrics and investor sentiment for ARDT.
15 Apr
Ardent Health (ARDT) narrative shifts as valuation resets and operations stabilize, signaling improved investor outlook and operational resilience. Valuation reset and steady operations represent a significant narrative shift likely to alter ARDT's trajectory and boost investor sentiment.
6 Mar
Ardent Health, Inc. (ARDT) released Q4 earnings call highlights detailing financial performance, operational updates, and future outlook. Q4 earnings highlights cover key financial results and strategic insights with significant potential to alter investor sentiment and company trajectory.
5 Mar
Ardent Health Inc (ARDT) reported record revenue in Q4 2025 earnings call, driven by strategic growth initiatives including expansions and partnerships. Record revenue and strategic growth demonstrate major financial strength and expansion momentum likely to boost investor confidence and stock performance.
Ardent Health (ARDT) released Q4 2025 earnings call transcript detailing quarterly financial results, full-year performance, management discussion, and forward-looking guidance. Q4 earnings transcript discloses comprehensive financial metrics, operational highlights, and strategic outlook, poised to significantly sway investor confidence and stock valuation.
Ardent Health Partners, LLC released Q4 2025 earnings call summary detailing financial performance, operational updates, and future outlook. Q4 earnings call summary discloses year-end financials, guidance, and strategic initiatives significantly influencing ARDT's trajectory and investor sentiment.
4 Mar
Ardent Health, Inc. (ARDT) reported fourth quarter 2025 results, highlighting financial performance for the period. Quarterly earnings releases drive substantial shifts in stock price and investor expectations for ARDT.
Ardent Health, Inc. (ARDT) reported Q4 earnings of $0.12 per share, missing the $0.25 consensus estimate, while revenue reached $1.42 billion, below the $1.50 billion forecast. Q4 earnings and revenue misses highlight weaker financial results, moderately affecting short-term stock performance and investor confidence.
28 Feb
Ardent Health (ARDT) faces securities class action lawsuits while advancing AI virtual nursing solutions, potentially reshaping its investment case amid legal challenges. Securities lawsuits create legal and financial risks, but AI virtual nursing innovations offer major strategic growth potential significantly altering ARDT's trajectory and investor sentiment.
25 Feb
Ardent Health partners with hellocare.ai to deploy enterprise-wide AI-assisted virtual physician, nursing, patient safety, and intelligent care delivery solutions. Enterprise AI partnership targets core healthcare operations, enabling major efficiency gains and competitive advantages in care delivery.
8 Feb
Ardent Health, Inc. (ARDT) is facing class action lawsuits and an accounting-related revenue restatement, raising concerns about its financial integrity and future performance. The lawsuits allege misleading financial practices, which could impact investor confidence and market perception. The revenue restatement may lead to adjustments in reported earnings, further complicating the company's financial outlook. Analysts are closely monitoring these developments as they could significantly influence Ardent's operational strategies and market standing. Class action lawsuits and a revenue restatement are likely to significantly impact investor sentiment and the company's financial trajectory.